Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 335

1.

Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.

Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Hibi T, Rutgeerts P; PURSUIT-SC Study Group.

Gastroenterology. 2014 Jan;146(1):85-95; quiz e14-5. doi: 10.1053/j.gastro.2013.05.048. Epub 2013 Jun 2.

PMID:
23735746
2.

Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.

Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Rutgeerts P; PURSUIT-Maintenance Study Group.

Gastroenterology. 2014 Jan;146(1):96-109.e1. doi: 10.1053/j.gastro.2013.06.010. Epub 2013 Jun 14.

PMID:
23770005
3.

Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis.

Rutgeerts P, Feagan BG, Marano CW, Padgett L, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Zhang H, Colombel JF, Reinisch W, Gibson PR, Sandborn WJ; PURSUIT-IV study group.

Aliment Pharmacol Ther. 2015 Sep;42(5):504-14. doi: 10.1111/apt.13291. Epub 2015 Jun 29.

4.

Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.

Carbonnel F, Colombel JF, Filippi J, Katsanos KH, Peyrin-Biroulet L, Allez M, Nachury M, Novacek G, Danese S, Abitbol V, Bossa F, Moreau J, Bommelaer G, Bourreille A, Fumery M, Roblin X, Reinisch W, Bouhnik Y, Brixi H, Seksik P, Malamut G, Färkkilä M, Coulibaly B, Dewit O, Louis E, Deplanque D, Michetti P, Sarter H, Laharie D; European Crohn's and Colitis Organisation; Groupe d'Étude Thérapeutique des Affections Inflammatoires Digestives.

Gastroenterology. 2016 Feb;150(2):380-8.e4. doi: 10.1053/j.gastro.2015.10.050. Epub 2015 Nov 26.

PMID:
26632520
5.

The impact of biological interventions for ulcerative colitis on health-related quality of life.

LeBlanc K, Mosli MH, Parker CE, MacDonald JK.

Cochrane Database Syst Rev. 2015 Sep 22;(9):CD008655. doi: 10.1002/14651858.CD008655.pub3. Review.

PMID:
26393522
6.

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.

Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB.

Gastroenterology. 2012 Feb;142(2):257-65.e1-3. doi: 10.1053/j.gastro.2011.10.032. Epub 2011 Nov 4.

PMID:
22062358
7.

Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.

Subramaniam K, Richardson A, Dodd J, Platten J, Shadbolt B, Pavli P.

Intern Med J. 2014 May;44(5):464-70. doi: 10.1111/imj.12397.

PMID:
24612209
8.

Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.

Bosca-Watts MM, Cortes X, Iborra M, Huguet JM, Sempere L, Garcia G, Gil R, Garcia M, Muñoz M, Almela P, Maroto N, Paredes JM.

World J Gastroenterol. 2016 Dec 21;22(47):10432-10439. doi: 10.3748/wjg.v22.i47.10432.

9.

Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.

Adedokun OJ, Xu Z, Marano CW, Strauss R, Zhang H, Johanns J, Zhou H, Davis HM, Reinisch W, Feagan BG, Rutgeerts P, Sandborn WJ.

J Crohns Colitis. 2017 Jan;11(1):35-46. doi: 10.1093/ecco-jcc/jjw133. Epub 2016 Jul 20.

10.

Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study.

Danese S, Rudziński J, Brandt W, Dupas JL, Peyrin-Biroulet L, Bouhnik Y, Kleczkowski D, Uebel P, Lukas M, Knutsson M, Erlandsson F, Hansen MB, Keshav S.

Gut. 2015 Feb;64(2):243-9. doi: 10.1136/gutjnl-2014-308004. Epub 2014 Oct 10.

PMID:
25304132
11.

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.

Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU; GO-AFTER study investigators.

Lancet. 2009 Jul 18;374(9685):210-21. doi: 10.1016/S0140-6736(09)60506-7. Epub 2009 Jun 26. Erratum in: Lancet. 2009 Oct 24;374(9699):1422.

PMID:
19560810
12.

Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, van Hoogstraten HJ, Chen AC, Zheng H, Danese S, Rutgeerts P.

Gastroenterology. 2014 Feb;146(2):392-400.e3.

PMID:
24512909
13.

Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.

Colombel JF, Sandborn WJ, Ghosh S, Wolf DC, Panaccione R, Feagan B, Reinisch W, Robinson AM, Lazar A, Kron M, Huang B, Skup M, Thakkar RB.

Am J Gastroenterol. 2014 Nov;109(11):1771-80. doi: 10.1038/ajg.2014.242. Epub 2014 Aug 26.

14.

Methotrexate for induction of remission in ulcerative colitis.

Chande N, Wang Y, MacDonald JK, McDonald JW.

Cochrane Database Syst Rev. 2014 Aug 27;(8):CD006618. doi: 10.1002/14651858.CD006618.pub3. Review.

PMID:
25162749
15.

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.

Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, Pazdur J, Bae SC, Palmer W, Zrubek J, Wiekowski M, Visvanathan S, Wu Z, Rahman MU; GO-FORWARD Study.

Ann Rheum Dis. 2009 Jun;68(6):789-96. doi: 10.1136/ard.2008.099010. Epub 2008 Dec 9. Erratum in: Ann Rheum Dis. 2011 Jan;70(1):238.

16.

Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis.

Detrez I, Dreesen E, Van Stappen T, de Vries A, Brouwers E, Van Assche G, Vermeire S, Ferrante M, Gils A.

J Crohns Colitis. 2016 May;10(5):575-81. doi: 10.1093/ecco-jcc/jjv241. Epub 2016 Jan 6.

17.

Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.

Lawson MM, Thomas AG, Akobeng AK.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005112. Review.

PMID:
16856078
18.

Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.

Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU.

Arthritis Rheum. 2009 Aug;60(8):2272-83. doi: 10.1002/art.24638. Erratum in: Arthritis Rheum. 2010 Oct;62(10):3005.

19.

Golimumab for moderately to severely active ulcerative colitis.

Kedia S, Ahuja V, Makharia GK.

Expert Rev Clin Pharmacol. 2016 Oct;9(10):1273-82. doi: 10.1080/17512433.2016.1221759. Epub 2016 Aug 18. Review.

PMID:
27498886
20.

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis.

Suzuki Y, Motoya S, Hanai H, Matsumoto T, Hibi T, Robinson AM, Mostafa NM, Chao J, Arora V, Camez A, Thakkar RB, Watanabe M.

J Gastroenterol. 2014 Feb;49(2):283-94. doi: 10.1007/s00535-013-0922-y. Epub 2013 Dec 24.

Supplemental Content

Support Center